Clinical Updates & Insights

The targeted therapy nirogacestat demonstrated rapid and sustained improvements for adults with progressing desmoid tumors, according to results from a...

You may have heard that the U.S. Food and Drug Administration (FDA) approved elacestrant for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer on January 27, 2023. In addition, the FDA also approved the Guardant360 CDx assay, a companion liquid biopsy diagnostic device for identifying patients for treatment.

A first-in-class allogeneic CAR T cell therapy regimen demonstrated feasibility and acceptable safety with preliminary evidence of efficacy in patients with heavily pretreated multiple myeloma, according to interim results from the phase 1 UNIVERSAL trial (NCT04093596) published recently in Nature Medicine.

Doctors at MSK Kids, the dedicated pediatric service at Memorial Sloan Kettering Cancer Center (MSK), pioneered many advances for pediatric patients in 2022.

Building on a legacy of pioneering and validating advances in spinal metastasis care, neurosurgeons and radiation oncologists with the Memorial Sloan Kettering Cancer Center (MSK) Multidisciplinary Spine Tumor Service have been investigating the clinical utility of genomic data as the next frontier for improving patient outcomes.

Read about some of the biggest scientific discoveries made by MSK researchers in 2022.

Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in many types of cancer treatment for patients in 2022. Here are some of the most important developments.

Neoadjuvant relatlimab and nivolumab achieved high response rates with a favorable safety profile in patients with advanced melanoma, according to initial data from a small clinical trial conducted by researchers at Memorial Sloan Kettering Cancer Center (MSK) and the University of Texas MD Anderson Cancer Center (MD Anderson).

Physicians at Memorial Sloan Kettering Cancer Center (MSK) have developed and validated clinical calculators to help patients estimate their likelihood of avoiding a recurrence after treatment for colorectal cancer.

Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough findings for new treatment approaches in several cancer indications at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9 to 13 in Paris. Highlights included clinically meaningful benefits for new treatment strategies in advanced bladder cancer, endometrial cancer, and renal cell carcinoma. Additionally, MSK experts shared their perspectives on previously reported groundbreaking trials of new treatment approaches in colorectal cancer and HER2-low metastatic breast cancer.